Fresenius Medical Care Ag · XETR:FME
Fresenius Medical Care — Investor Presentation (June 2019)
26 slides from Fresenius Medical Care's investor presentation, Jun 27, 2019
Slide 1: St. Wendel, June 27, 2019
ST. WENDEL JUNE 27, 2019 Kent Wanzek – CEO Global Manufacturing, Quality & Supply, Member of the FME Management Board Peter Palmqvist – SVP Production Area EMEA Gerhard Breith – SVP St. Wendel Plant Operations © Copyright
Slide 2: Safe harbor statement
Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncert
Slide 3: Agenda
1 GMQS STRATEGY AGENDA 2 PRODUCTION FOOTPRINT 3 EMEA REGION 4 ST. WENDEL PLANT
Slide 4: GMQS Strategy
” FRESENIUS Y MEDICAL CARE GMQS STRATEGY
Slide 5: Strategy – FME Core Competencies
STRATEGY – FME CORE COMPETENCIES INNOVATING PRODUCTS STANDARDIZING MEDICAL PROCEDURES COORDINATING PATIENTS EFFICIENTLY OPERATING OUTPATIENT FACILITIES St. Wendel – Plant Visit Page 5
Slide 6: Treatment Options: Hemodialysis
TREATMENT OPTIONS COMPONENTS HEMODIALYSIS At a dialysis center or hospital, the medical staff will prepare, perform and monitor the treatment. Hemodialysis in a center usually takes place three times a week and lasts approximately four hours for each session plus travel time to and from the cent
Slide 7: Treatment Options: Peritoneal Dialysis
TREATMENT OPTIONS COMPONENTS PERITONEAL DIALYSIS A permanent tube, or catheter, is inserted into the peritoneal cavity. Through which, dialysis fluid is fed into the cavity and left to absorb the impurities from the blood. Later, the fluid is drained-off into a bag and replaced with fresh fluid. S
Slide 8: Advantage of Being a Vertical Integrated Company
ADVANTAGE OF BEING A VERTICAL INTEGRATED COMPANY Research & Development Production Evaluation Products & of Treatment Therapies Outcome Clinical Dialysis Databases Services St. Wendel – Plant Visit Page 8
Slide 9: Our Values
OUR VALUES OUR VALUES WHEEL At Fresenius Medical Care, it is our purpose to „Create a future worth living. For patients. Worldwide. Every day“. Our Core Values Coll- aborative, Proactive, Reliable and Excellent are the basis for and guide us in our daily work to achieve this purpose togehter. St. We
Slide 10: GMQS Strategic Pillars
GMQS STRATEGIC PILLARS RELIABLE LEVERAGED PRODUCT QUALITY DELIVERED COST GMQS Strategic Pillars EFFECTIVE CAPITAL PRODUCT SUPPLY EFFICIENCY St. Wendel – Plant Visit Page 10
Slide 11: 2018: GMQS Facts
2018: GMQS FACTS Quality GMQS Employees Products (produced & delivered) consistently between 5 & 6 sigma >17,000 in 34 production sites worldwide quality/service levels Production Output 140,000,000 Product offerings Dialyzers ~160 Countries 1 in 2 HD machines produced by FME St. Wendel – Plant Visi
Slide 12: Global Manufacturing, Quality & Supply Leadership
GLOBAL MANUFACTURING, QUALITY & SUPPLY CEO GMQS AND MEMBER OF THE MANAGEMENT BOARD Kent D. Wanzek CEO GMQS, Management Board Member, FME Mgmt. AG Claudia Elling Manager, Office of the CEO GMQS Arnold Pieper Juergen Suenkel Troy McGhee Joe Winslow CFO/SVP Financial Services SVP Strategy & Industrial
Slide 13: Production Footprint
” FRESENIUS Y MEDICAL CARE PRODUCTION FOOTPRINT
Slide 14: Global Production Network: Major Plants
GLOBAL PRODUCTION NETWORK MAJOR PLANTS Schweinfurt Knoxville St. Wendel Changshu Ogden LÁrbresle Vrsac Palazzo Pignano Antalya Concord Buzen Reynosa Bogotá Dialyzers/Fibers PD Solutions/Salines Enstek Hardware Concentrates Bloodlines Plants with Major Projects >€10m between 2013 – 2018 Other GMQS Pl
Slide 15: Product Range
PRODUCT RANGE Hemodialysis Machines Peritoneal Dialysis Disposables (inc. NxStage) (Solutions & Cyclers) Dialyzers, Concentrates/Solutions, Bloodlines/Cassette Systems Water Treatment (VIVONIC) Extrapulmonary Vascular Access Heart & Lung Support (Catheter, Humacyte) (XENIOS) St. Wendel – Plant Visit
Slide 16: EMEA Region
2” FRESENIUS ww v MEDICAL CARE EMEA REGION
Slide 17: GMQS EMEA Execution of Strategy
GMQS EMEA EXECUTION OF STRATEGY SUPPLY QUALITY COST PEOPLE St. Wendel – Plant Visit Page 17
Slide 18: EMEA Execution of Strategy – Quality
EMEA EXECUTION OF STRATEGY – FOCUS AND CONTINUOUS IMPROVEMENT Deliver product quality to patients is our passion and first priority Operational excellence through Daily shop floor management and LEAN/Six Sigma Operational reviews with “next practice” implementation and shared knowledge across
Slide 19: EMEA Execution of Strategy – Supply
EMEA EXECUTION OF STRATEGY – FOCUS AND CONTINUOUS IMPROVEMENT On time installation and ramp up of plants and manufacturing equipment and never constrain sales On time delivery of products with the right quality in all steps of the supply chain Agile capacity utilization to optimize working SUP
Slide 20: EMEA Execution of Strategy – Cost
EMEA EXECUTION OF STRATEGY – FOCUS AND CONTINUOUS IMPROVEMENT Optimization of productivity in existing production equipment and organizations Automation of manual operations in high cost environment (Dialyzers & PD-solutions) Transfer of manual work to attractive cost environment (Blood lines)
Slide 21: EMEA Execution of Strategy – People
EMEA EXECUTION OF STRATEGY – FOCUS AND CONTINUOUS IMPROVEMENT The right person in the right place at the right time Competence development & Succession planning Develop resources and competence in-house to enable us to grow globally PEOPLE Live our Core values and enhance a performance cultu
Slide 22: St. Wendel Plant
” FRESENIUS Y MEDICAL CARE ST. WENDEL PLANT
Slide 23: General Information St. Wendel Plant
GENERAL INFORMATION ST. WENDEL PLANT Golden quality standard of medical and pharmaceutical products High-end automation with technology leadership Manufacturing 4.0 and AI in practice Execution of highest efficiencies Continuous expansion approach since 1974 St. Wendel – Plant Visit Page 23
Slide 24: Key Numbers of St. Wendel Plant for 2019
KEY NUMBERS OF ST. WENDEL PLANT FOR 2019 Employees (May 2019): 2,060 Areas: Production, GRD, Technology Dev., IP, Apprentices Revenue: >400 Mio EUR Value on COP base Products produced (examples): >61 Mio filters >30.6 Mio PD systems CAPEX: >74 Mio EUR (2019) Land Area: >140,000 m² Certificates: FDA/
Slide 25: St. Wendel Plant Layout
ST. WENDEL PLANT LAYOUT St. Wendel – Plant Visit Page 25
Slide 26: Thank you for your attention! Let's start our tour
THANK YOU FOR YOUR ATTENTION! LET’S START OUR TOUR © Copyright
Fresenius Medical Care — Investor Presentation (June 2019) on 6ix